In the BioHarmony Drug Report Database
Marinol, Syndros (dronabinol) is a small molecule pharmaceutical. Dronabinol was first approved as Marinol on 1985-05-31. It is used to treat anorexia, nausea, and vomiting in the USA. The pharmaceutical is active against cannabinoid receptor 1. In addition, it is known to target glycine receptor subunit alpha-3, glycine receptor subunit alpha-2, glycine receptor subunit alpha-1, transient receptor potential cation channel subfamily M member 8, N-arachidonyl glycine receptor, G-protein coupled receptor 55, cannabinoid receptor 2, transient receptor potential cation channel subfamily A member 1, transient receptor potential cation channel subfamily V member 2, and fatty acid-binding protein, liver. Dronabinol’s patent is valid until 2028-08-06 (FDA).
Image (chem structure or protein)